마황을 포함하지 않은 한약처방 단일중재에 의한 단순비만 치료 : 증례보고

키워드

참고문헌 (48)

1. Heymsfield SB, "Mechanisms, Pathophysiology, and Management of Obesity", N Engl J Med, 376(15), pp.1492~ (2017)
2. González-Muniesa P, "Obesity", Nat Rev Dis Primers, 3, pp.17034~ (2017)
3. EBM-based Obesity KMCPG Development Committee, "KMCPG-Obesity" (2016), Elsevier Korea
4. 정장원, "인체를 대상으로 한 한의학적 비만 연구의 최신 국내 동향분석", 한방재활의학과학회지, 26(1), pp.49~61 (2016), 한방재활의학과학회
5. Song MY, "The Safety Guidelines for use of Ma-huang in Obesity Treatment", Journal of Korean Oriental Association for Study of Obesity, 6(2), pp.17~27 (2006)
6. 조가원, "비만 치료에서 마황 및 에페드린의 유효성, 안전성에 대한 고찰 - RCT 연구를 중심으로 -", 대한한의학회지, 38(3), pp.170~184 (2017), 대한한의학회[DOI]
7. Zell-Kanter M, "Reduction in ephedra poisonings after FDA ban", N Engl J Med, 372(22), pp.2172~2174 (2015)
8. Hallas J, "Use of a prescribed ephedrine", caffeine combination and the risk of serious cardiovascular events : a registry-based case-crossover study, 2008, pp.168(8), 966~973
9. Liu Y, "Herbal Medicine for the Treatment of Obesity : An Overview of Scientific Evidence from 2007 to 2017", Evid Based Complement Alternat Med, 2017, pp.8943059~ (2017)
10. Fu C, "Natural Products with Anti-obesity Effects and Different Mechanisms of Action", J Agric Food Chem, 64(51), pp.9571~9585 (2016)
11. Martel J, "Anti-obesogenic and antidiabetic effects of plants and mushrooms", Nat Rev Endocrinol, 13(3), pp.149~160 (2017)
12. Daneschvar HL, "FDA-Approved Anti-Obesity Drugs in the United States", Am J Med, 129(8), pp.879~ (2016)
13. Pi-Sunyer X, "A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management", N Engl J Med, 373(1), pp.11~22 (2015)
14. Nuffer WA, "Liraglutide : A New Option for the Treatment of Obesity", Pharmacotherapy, 35(10), pp.926~934 (2015)
15. Zhen Z, "Anti-diabetic effects of a Coptis chinensis containing new traditional Chinese medicine formula in type 2 diabetic rats", Am J Chin Med, 39(1), pp.53~63 (2011)
16. Lian F, "Chinese herbal medicine Tianqi reduces progression from impaired glucose tolerance to diabetes : a double-blind, randomized, placebo-controlled, multicenter trial", J Clin Endocrinol Metab, 99(2), pp.648~655 (2014)
17. Tong XL, "The safety and effectiveness of TM81, a Chinese herbal medicine, in the treatment of type 2 diabetes : a randomized double-blind placebo-controlled trial", Diabetes Obes Metab, 15(5), pp.448~454 (2013)
18. Yu Y, "Berberine induces GLP-1 secretion through activation of bitter taste receptor pathways", Biochem Pharmacol, 97(2), pp.173~177 (2015)
19. Al-masri IM, "Inhibition of dipeptidyl peptidase IV(DPP IV)is one of the mechanisms explaining the hypoglycemic effect of berberine", J Enzyme Inhib Med Chem, 24(5), pp.1061~1066 (2009)
20. Gao Y, "Recent progress in natural products as DPP-4 inhibitors", Future Med Chem, 7(8), pp.1079~1089 (2015)
21. Sui Y, "A systematic review on use of Chinese medicine and acupuncture for treatment of obesity", Obes Rev, 13(5), pp.409~430 (2012)
22. Hasani-Ranjbar S, "A systematic review of anti-obesity medicinal plants-an update", J Diabetes Metab Disord, 12(1), pp.28~ (2013)
23. Xu L, "Chinese Medicine in the Battle Against Obesity and Metabolic Diseases", Front Physiol, 9, pp.850~ (2018)
24. Al-masri IM, "Inhibition of dipeptidyl peptidase IV(DPP IV)is one of the mechanisms explaining the hypoglycemic effect of berberine", J Enzyme Inhib Med Chem, 24(5), pp.1061~1066 (2009)
25. Yu Y, "Modulation of glucagon-like peptide-1 release by berberine : in vivo and in vitro studies", Biochem Pharmacol, 79(7), pp.1000~1006 (2010)
26. Zhang Y, "Geniposide acutely stimulates insulin secretion in pancreatic β-cells by regulating GLP-1 receptor", cAMP signaling and ion channels, 2016, pp.430, 89~96
27. Brunton S, "GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes:is one approach more successful or preferable than the other?", Int J Clin Pract, 68(5), pp.557~567 (2014)
28. Xu L, "Natural products for the treatment of type 2 diabetes mellitus : Pharmacology and mechanisms", Pharmacol Res, 130, pp.451~465 (2018)
29. Pang B, "Effect of Rhizoma coptidis(Huang Lian)on Treating Diabetes Mellitus", Evid Based Complement Alternat Med, 2015, pp.921416~ (2015)
30. Milaneschi Y, "Depression and obesity : evidence of shared biological mechanisms", Mol Psychiatry, 24(1), pp.18~33 (2019)
31. Ren L, "Rapid antidepressant effects of Yueju : A new look at the function and mechanism of an old herbal medicine", J Ethnopharmacol, 203, pp.226~232 (2017)
32. Liu J, "Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathway", Neurochem Int, 51(6-7), pp.361~369 (2007)
33. Zhang CY, "Genipin inhibits UCP2-mediated proton leak and acutely reverses obesity-and high glucose-induced beta cell dysfunction in isolated pancreatic islets", Cell Metab, 3(6), pp.417~427 (2006)
34. Guan L, "Genipin ameliorates diet-induced obesity via promoting lipid mobilization and browning of white adipose tissue in rats", Phytother Res, 32(4), pp.723~732 (2018)
35. Shan M, "A Review on the Phytochemistry, Pharmacology, Pharmacokinetics and Toxicology of Geniposide, a Natural Product", Molecules, 22(10), pp.1689~ (2017)
36. Berman AY, "The therapeutic potential of resveratrol : a review of clinical trials", NPJ Precis Oncol, 1, pp.35~ (2017)
37. 김정목, "AMPK activators: mechanisms of action and physiological activities", Experimental and Molecular Medicine, 48, pp.1~12 (2016), 생화학분자생물학회
38. Wang L, "Salvia miltiorrhiza : A Potential Red Light to the Development of Cardiovascular Diseases", Curr Pharm Des, 23(7), pp.1077~1097 (2017)
39. Camacho S, "Anti-obesity and anti-hyperglycemic effects of cinnamaldehyde via altered ghrelin secretion and functional impact on food intake and gastric emptying", Sci Rep, 5, pp.7919~ (2015)
40. Zuo J, "Cinnamaldehyde Ameliorates Diet-Induced Obesity in Mice by Inducing Browning of White Adipose Tissue", Cell Physiol Biochem, 42(4), pp.1514~1525 (2017)
41. Alam MA, "Effect of citrus flavonoids, naringin and naringenin, on metabolic syndrome and their mechanisms of action", Adv Nutr, 5(4), pp.404~417 (2014)
42. Ye XP, "α-Glucosidase and α-Amylase Inhibitory Activity of Common Constituents from Traditional Chinese Medicine Used for Diabetes Mellitus", Chinese Journal of Natural Medicines, 8(5), pp.349~352 (2010)
43. Seyedan A, "Medicinal Plants and Their Inhibitory Activities against Pancreatic Lipase : A Review", Evid Based Complement Alternat Med, 2015, pp.973143~ (2015)
44. Hu J, "Mapping the knowledge of international Chinese medicines treatment on type 2 diabetes : A biblimetrical study", Journal of Traditional Chinese Medical Sciences, 3(4), pp.263~272 (2016)
45. Thaiss CA, "Persistent microbiome alterations modulate the rate of post-dieting weight regain", Nature, 540(7634), pp.544~551 (2016)
46. van Baak MA, "Mechanisms of weight regain after weight loss - the role of adipose tissue", Nat Rev Endocrinol, 15(5), pp.274~287 (2019)
47. Tong X, "Structural Alteration of Gut Microbiota during the Ameliorationof Human Type 2 Diabetes with Hyperlipidemia by Metformin and a Traditional Chinese Herbal Formula : a Multicenter, Randomized, Open Label Clinical Trial", MBio, 9(3), pp.e02392~e02417 (2018)
48. Wei X, "Xiexin Tang improves the symptom of type 2 diabetic rats by modulation of the gutmicrobiota", Sci Rep, 8(1), pp.3685~ (2018)

관련 논문AI추천